de Oliveira Kamila Botelho Sampaio, Leite Michel Lopes, Melo Nadielle Tamires Moreira, Lima Letícia Ferreira, Barbosa Talita Cristina Queiroz, Carmo Nathalia Lira, Melo Douglas Afonso Bittencourt, Paes Hugo Costa, Franco Octávio Luiz
Centro de Análises Proteômicas e Bioquímicas, Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Federal District, Brasilia 71966-700, Brazil.
S-Inova Biotech, Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande 79117-900, Brazil.
Antibiotics (Basel). 2024 Nov 4;13(11):1042. doi: 10.3390/antibiotics13111042.
The extensive use of antibiotics during recent years has led to antimicrobial resistance development, a significant threat to global public health. It is estimated that around 1.27 million people died worldwide in 2019 due to infectious diseases caused by antibiotic-resistant microorganisms, according to the WHO. It is estimated that 700,000 people die each year worldwide, which is expected to rise to 10 million by 2050. Therefore, new and efficient antimicrobials against resistant pathogenic bacteria are urgently needed. Antimicrobial peptides (AMPs) present a broad spectrum of antibacterial effects and are considered potential tools for developing novel therapies to combat resistant infections. However, their clinical application is currently limited due to instability, low selectivity, toxicity, and limited bioavailability, resulting in a narrow therapeutic window. Here we describe an overview of the clinical application of AMPs against resistant bacterial infections through nanoformulation. It evaluates metal, polymeric, and lipid AMP delivery systems as promising for the treatment of resistant bacterial infections, offering a potential solution to the aforementioned limitations.
近年来抗生素的广泛使用导致了抗菌药物耐药性的产生,这对全球公共卫生构成了重大威胁。据世界卫生组织估计,2019年全球约有127万人死于由抗生素耐药微生物引起的传染病。据估计,全球每年有70万人死亡,预计到2050年这一数字将增至1000万。因此,迫切需要针对耐药病原菌的新型高效抗菌药物。抗菌肽(AMPs)具有广谱抗菌作用,被认为是开发抗耐药感染新疗法的潜在工具。然而,由于其稳定性差、选择性低、毒性大以及生物利用度有限,导致治疗窗口狭窄,目前其临床应用受到限制。在此,我们概述了通过纳米制剂将抗菌肽用于抗耐药细菌感染的临床应用。它评估了金属、聚合物和脂质抗菌肽递送系统在治疗耐药细菌感染方面的前景,为上述局限性提供了潜在的解决方案。